

Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (Text with EEA relevance) (revoked)

CHAPTER II

MAKING AVAILABLE ON THE MARKET AND PUTTING INTO SERVICE OF DEVICES, OBLIGATIONS OF ECONOMIC OPERATORS, REPROCESSING, CE MARKING, FREE MOVEMENT

Article 12

Change of authorised representative

.....

Textual Amendments applied to the whole legislation

- F1** Regulation revoked (31.12.2020) by [The Medical Devices Regulations 2002](#) (S.I. 2002/618), **reg. 40** (with savings and transitional provisions for N.I. in [reg. 3ZA](#)) (as amended by [S.I. 2019/791](#), regs. 1(1), **3(7)**) and by [S.I. 2020/1478](#), regs. 1(3), **Sch. 2 para. 2**; and as amended (27.7.2021) by [The Medical Devices \(Northern Ireland Protocol\) Regulations 2021](#) (S.I. 2021/905), regs. 1(2), 4, **32**; 2020 c. 1, **Sch. 5 para. 1(1)**)

Status:

This version of this provision no longer has effect.

Changes to legislation:

There are currently no known outstanding effects for the Regulation (EU) 2017/745 of the European Parliament and of the Council, Article 12.